Identification of ST7 Alteration Profile, Frequency of Alteration and Correlation with ST7-Related Genes using TCGA Data

Nurdina CHARONG; Moltira PROMKAN

doi:10.48048/wjst.2019.6226

Authors

Nurdina CHARONG Department of Medical Technology, School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80161
Moltira PROMKAN Department of Clinical Microscopy, Faculty of Medical Technology, Mahidol University, Nakhon Pathom 73170

DOI:

https://doi.org/10.48048/wjst.2019.6226

Keywords:

Co-occurrence, Gene alteration, ST7, TCGA

Abstract

ST7 (Suppression of Tumorigenicity 7) was reported as a protein playing a role in maintaining cellular structure. This study aims to investigate the ST7 alteration profiles and frequency of alteration in different cancers using data from The Cancer Genome Atlas (TCGA). The correlation between alterations of ST7 and angiogenesis-related genes, SERPINE1, MMP13, and VEGFA, was determined and the relation between ST7 and genes involved in suppression of ST7 transcription, PRMT5 and SMARCA4, were also analyzed. Data of 6 cancer groups from The Cancer Genome Atlas (TCGA) including ovarian serous cystadenocarcinoma (OSC), liver hepatocellular carcinoma (LHC), bladder urothelial adenocarcinoma (BUA), stomach adenocarcinoma (SC), prostate adenocarcinoma (PRAD) and glioblastoma multiforme (GBM) were downloaded for this study. The results indicated that 3 alteration patterns including amplification, missense mutation, and deletion were observed in 6 cancer studies. Gene pair between ST7 and SERPINE1 indicated the co-occurrent alteration in BUC, OSC and SC (p < 0.05). However, no association between alterations of these 2 genes and survival events in our study was observed. Shorter overall survival rate and disease-free survival were found in BUC patients with ST7, PRMT5, and SMARCA4 alterations. These findings suggest that using TCGA data can target the potential genes involved in carcinogenesis. Combining ST7 with PRMT5 and SMARCA4 could be used as indicators for analyzing the patient survival in BUC patients and may serve as the potential therapeutic target for cancer in the future.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

J Zenklusen and C Conti. Cytogenetic, molecular and functional evidence for novel tumor suppressor genes on the long arm of human chromosome 7. MolCarcinog 1996; 15, 167-75.

J Zenklusen, C Conti and E Green. Mutational and functional analyses reveal that ST7 is a highly conserved tumor-suppressor gene on human chromosome 7q31. Nat. Genet. 2001; 27, 392-8.

CS-F Hooi, C Blancher, W Qiu, IM Revet, LH Williams, ML Ciavarella, RL Anderson, EW Thompson, A Connor, WA Phillips and IG Campbell. ST7 mediated suppression of tumorigenicity of prostate cancer cells is characterized by remodeling of the extracellular matrix. Oncogene 2006; 25, 3924-33.

N Thomas, D Choong, V Jokubaitis, P Neville and I Campbell. Mutation of the ST7 tumor suppressor gene on 7q31.1 is rare in breast, ovarian and colorectal cancers. Nat. Genet. 2001; 29, 379-80.

K Hughes, A Hurlstone, E Tobias, R McFarlane and D Black. Absence of ST7 mutations in tumor-derived cell lines and tumors. Nat. Genet. 2001; 29, 380-1.

V Brown, C Proby, D Barnes and D Kelsell. Lack of mutations within ST7 gene in tumour-derived cell lines and primary epithelial tumours. Br. J. Cancer 2002; 87, 208-11.

S Dong and D Sidransky. Absence of ST7 gene alterations in human cancer. Clin. Cancer Res. 2002; 8, 2939-41.

C Lu, HM Xu, Q Ren, Y Ao, ZN Wang, X Ao, L Jiang, Y Luo and X Zhang. Somatic mutation analysis of p53 and ST7 tumor suppressor genes in gastric carcinoma by DHPLC. World J. Gastro. Enterol. 2003; 9, 2662-5.

J Gao, BA Aksoy, U Dogrusoz, G Dresdner, B Gross, S Sumer, Y Sun, A Jacobsen, R Sinha, E Larsson, E Cerami, C Sander and N Schultz. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 2013; 6, 11.

E Cerami, J Gao, U Dogrusoz, B Gross, S Sumer, B Aksoy, A Jacobsen, C Byrne, M Heuer, E Larsson, Y Antipin, B Reva, A Goldberg, C Sander and N Schultz. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2, 401-4.

JD Vassalli, AP Sappino and D Belin. The plasminogen activator/plasmin system. J. Clin. Invest. 1991; 88, 1067-72.

MF Leeman, S Curran and GI Murray. The structure, regulation, and function of human matrix metalloproteinase-13. Crit. Revb. Biochem. Mol. Biol. 2003; 37, 149-66.

N Charong, P Patmasiriwat and J Zenklusen. Localization and characterization of ST7 in cancer. J. Cancer Res. Clin. Oncol. 2011; 137, 89-97.

DR Senger, SJ Galli and AM Dvorak. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219, 983-5.

S Pal, S Vishwanath, H Erdjument-Bromage, P Tempst and S Sif. Human SWI/SNFassociated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol. Cell Biol. 2004; 24, 9630-45.

JS Lee. Exploring cancer genomic data from the cancer genome atlas project. BMB Rep. 2016; 49, 607-11.